Next-generation sequencing (NGS) technology improves upon traditional Sanger sequencing, giving researchers higher sensitivity and throughput with lower costs. Using NGS, researchers discovered many new genes with low or moderate risk for hereditary cancers. As such, whole-exome sequencing (WES) and whole-genome sequencing (WGS) powered multi-gene panels have become part of clinical diagnostics and cancer genetic testing. However, scientists must be aware that problems still persist when it comes to clinical utility, actionability, and validity that need to be addressed in a case-specific manner.
Download this application note from QIAGEN to learn where and how caution should be exercised in using multi-gene panels for clinical applications.
